Beta Drugs Limited (NSE:BETA)

Market Cap	16.25B
Revenue (ttm)	3.35B
Net Income (ttm)	410.00M
Shares Out	9.61M
EPS (ttm)	42.65
PE Ratio	39.63
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,400
Average Volume	5,140
Open	1,700.00
Previous Close	1,716.10
Day's Range	1,666.05 - 1,750.00
52-Week Range	892.35 - 1,860.00
Beta	0.49
RSI	45.48
Earnings Date	Apr 25, 2025

About Beta Drugs

Beta Drugs Limited develops, manufactures, and sells anti-cancer drugs in India. The company offers oncology products in the areas of breast, lung, head and neck, colorectal, ovarian, gastric, testicular, renal, and prostate cancer, as well as brain tumor, leukemia, lymphoma, myeloma, and supportive cancer; and dermatology products. It also develops active pharmaceutical ingredients. The company exports its products. Beta Drugs Limited was incorporated in 2005 and is based in Panchkula, India.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2005
• Employees: 371
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: BETA

Financial Performance

In 2023, Beta Drugs's revenue was 2.96 billion, an increase of 30.21% compared to the previous year's 2.27 billion. Earnings were 364.37 million, an increase of 18.62%.